Researchers have discovered a new link between the Epstein-Barr virus (EBV) and the progression of multiple sclerosis (MS). Their study revealed that certain antibodies, originally aimed at fighting EBV, can mistakenly target proteins in the brain and spinal cord, leading to MS symptoms. This antibody misdirection was found in roughly 23% of MS patients studied. The findings highlight the need for personalized therapies to combat MS.
